Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient
Last updated on April 2022Recruitment
- Recruitment Status
- Unknown status
Inclusion Criteria
- WHO activity score between 0 and 2.
- life expectancy exceeding 12 weeks
- EGFR mutation status known with no activating EGFR mutation
- ...
- WHO activity score between 0 and 2.
- life expectancy exceeding 12 weeks
- EGFR mutation status known with no activating EGFR mutation
- NSCLC proved by a histological biopsy
- age over superior to 18
- indication of erlotinib therapy after at least one previous therapy
- patients who have signed an informed consent to participate in this study
Exclusion Criteria
- other malignant disease
- life expectancy less than 12 weeks
- refusal to sign the consent
- ...
- other malignant disease
- life expectancy less than 12 weeks
- refusal to sign the consent
- major adults protected by French law
- contraindication for the initiation of erlotinib
- progressive inflammatory disease
- infection with the HIV virus
Summary
- Conditions
- No EGFR Activating Mutation
- Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- WHO activity score between 0 and 2.
- life expectancy exceeding 12 weeks
- EGFR mutation status known with no activating EGFR mutation
- ...
- WHO activity score between 0 and 2.
- life expectancy exceeding 12 weeks
- EGFR mutation status known with no activating EGFR mutation
- NSCLC proved by a histological biopsy
- age over superior to 18
- indication of erlotinib therapy after at least one previous therapy
- patients who have signed an informed consent to participate in this study
Exclusion Criteria
- other malignant disease
- life expectancy less than 12 weeks
- refusal to sign the consent
- ...
- other malignant disease
- life expectancy less than 12 weeks
- refusal to sign the consent
- major adults protected by French law
- contraindication for the initiation of erlotinib
- progressive inflammatory disease
- infection with the HIV virus
Tracking Information
- NCT #
- NCT02069418
- Collaborators
- University Hospital, Tours
- Army Hospital, Percy
- Créteil Hospital
- University Hospital, Rouen
- Central Hospital, Nancy, France
- University Hospital, Toulouse
- University Hospital, Bordeaux
- Investigators
- Principal Investigator: José HUREAUX, MD, PhD University Hospital, Angers Study Chair: Olivier COUTURIER, MD, PhD University Hospital, Angers
- José HUREAUX, MD, PhD University Hospital, Angers Study Chair: Olivier COUTURIER, MD, PhD University Hospital, Angers
Get Well Soon